JP2016525560A5 - - Google Patents

Info

Publication number

JP2016525560A5

JP2016525560A5 JP2016530509A JP2016530509A JP2016525560A5 JP 2016525560 A5 JP2016525560 A5 JP 2016525560A5 JP 2016530509 A JP2016530509 A JP 2016530509A JP 2016530509 A JP2016530509 A JP 2016530509A JP 2016525560 A5 JP2016525560 A5 JP 2016525560A5

Authority

JP

Japan

Prior art keywords

conjugate

seq

use according

sequence

cell binding

Prior art date

2014-07-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 239000011230 binding agent Substances 0.000 claims 11
• 231100000599 cytotoxic agent Toxicity 0.000 claims 8
• 229940127089 cytotoxic agent Drugs 0.000 claims 8
• 239000002254 cytotoxic agent Substances 0.000 claims 8
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 5
• 201000011510 cancer Diseases 0.000 claims 5
• 239000012634 fragment Substances 0.000 claims 5
• 206010006187 Breast cancer Diseases 0.000 claims 4
• 208000026310 Breast neoplasm Diseases 0.000 claims 4
• 108090000288 Glycoproteins Proteins 0.000 claims 4
• 102000003886 Glycoproteins Human genes 0.000 claims 4
• 239000005022 packaging material Substances 0.000 claims 4
• 206010033128 Ovarian cancer Diseases 0.000 claims 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
• 230000008033 biological extinction Effects 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
• 229930126263 Maytansine Natural products 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• -1 N-succinimidyl pyridyl Chemical group 0.000 claims 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
• 238000002835 absorbance Methods 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229940011871 estrogen Drugs 0.000 claims 1
• 239000000262 estrogen Substances 0.000 claims 1
• 206010023332 keratitis Diseases 0.000 claims 1
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
• 229960003387 progesterone Drugs 0.000 claims 1
• 239000000186 progesterone Substances 0.000 claims 1
• 102000005962 receptors Human genes 0.000 claims 1
• 108020003175 receptors Proteins 0.000 claims 1
• 125000002456 taxol group Chemical group 0.000 claims 1
• 231100000167 toxic agent Toxicity 0.000 claims 1
• 239000003440 toxic substance Substances 0.000 claims 1
• 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1